REPLICEL LIFE SCIENCES INC.
Disclosed SEC business address
SUITE 900 - 570 GRANVILLE STREET, VANCOUVER BC, A1, V6C 3P1
REPLICEL LIFE SCIENCES INC. (ticker CIK0001205059, CIK 0001205059) is tracked by Global Barry from its public SEC filings and disclosures. Disclosed industry classification: Biological Products, (No Diagnostic Substances) (SIC 2836). Disclosed business address country: British Columbia, Canada. Every item is grounded on the cited public source — no figures are fabricated.
Full evidence detail
Company deep views this month: 2 of 5.
Filing intelligence
20 filings ingested; deep FILING ANALYSIS shown for 6 filings.
- FACT Only one ingested version of this accession exists; no intra-document revisions have been observed. Change tracking for this filing requires ≥2 ingested versions. 2023-04-20 source ↗
- ANALYSIS This SC 13D was filed 84 days after the previous ingested SC 13D (2023-01-26). 18 filings of this type are ingested. 2023-04-20 source ↗
- UNKNOWN Changed risk-factor language (Item 1A): not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2023-04-20 source ↗
- UNKNOWN MD&A highlights: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2023-04-20 source ↗
- UNKNOWN Material business developments: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2023-04-20 source ↗
- UNKNOWN Debt / capital-structure changes: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2023-04-20 source ↗
- UNKNOWN Acquisitions / divestitures: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2023-04-20 source ↗
- UNKNOWN Litigation / regulatory matters: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2023-04-20 source ↗
Latest developments
Most recent SEC filing events ingested for this company (newest first).
- FACT SC 13D/A filed 2023-04-20 source ↗
- FACT SC 13D/A filed 2023-01-26 source ↗
- FACT SC 13D/A filed 2023-01-05 source ↗
- FACT SC 13D filed 2022-09-29 source ↗
- FACT SC 13D/A filed 2022-06-02 source ↗
- FACT SC 13D/A filed 2021-12-21 source ↗
- FACT SC 13D filed 2021-06-04 source ↗
- FACT SC 13D/A filed 2020-09-17 source ↗
- FACT SC 13D filed 2018-09-12 source ↗
- FACT S-8 filed 2013-05-21 source ↗
Insider ownership filings
No insider ownership filings (Forms 3/4/5) have been ingested for this company. This is not a claim that none exist.
- UNKNOWN No insider ownership filings (Forms 3/4/5) have been ingested for this company. This is not a claim that none exist.
Geographic footprint (disclosed)
Geographic footprint limited to locations disclosed in ingested evidence.
- FACT Principal executive office (disclosed): VANCOUVER BC, A1, V6C 3P1
- FACT Mailing address (disclosed): VANCOUVER BC, A1, V6C 3P1
- FACT State/country of incorporation (disclosed): British Columbia, Canada
Industry classification (disclosed)
Industry classification as disclosed by the issuer's SEC record.
- FACT Primary industry (disclosed SIC): Biological Products, (No Diagnostic Substances) (SIC 2836)
- FACT SEC filer category: Non-accelerated filer
Supply chain
No supplier or customer relationships are disclosed in ingested evidence. Supply-chain relationships are shown only when explicitly disclosed and cited; undisclosed relationships are never inferred.
- UNKNOWN No supplier or customer relationships are disclosed in ingested evidence. Supply-chain relationships are shown only when explicitly disclosed and cited; undisclosed relationships are never inferred.
Risk factors
Risk-factor language requires ingested filing document bodies.
- UNKNOWN Risk-factor language requires ingested filing document bodies.
Sources
- U.S. Securities and Exchange Commission, EDGAR · filing index · retrieved 2026-10-19T21:30:50.551113+00:00
- SEC EDGAR · issuer filing index
Grounded on public SEC filings and disclosures with explicit evidence tiers and citations. This page is informational only and is not investment advice. No figures are fabricated; unavailable data is shown as unavailable.